EUVIMEDEUVIMED entdecken
Crossref

A Novel PSMA/FAP-Specific Radiotracer 99mTc-HFaPSMA for Diagnosis of PSMA-Negative Prostate Cancer: From Preclinical Validation to Clinical Translation

Yuchen Wang, Xinru Li, Chenzhen Li, Huiyuan Xing, Rui Gao, Bing Jia iD

Journal of Medicinal Chemistry · 28.08.2025 · 68 (16) · 17598-17610

DOI: 10.1021/acs.jmedchem.5c01294 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 09.08.2025. Verfasst von Yuchen Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Medicine, School of Basic Medical Sciences, Peking University, Beijing 100191, China. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Glutamate Carboxypeptidase II, Radiopharmaceuticals, Antigens, Surface. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In this study, we reported a bispecific radiotracer [99mTc]Tc-HFaPSMA to improve the diagnostic sensitivity of prostate cancer (PCa). [99mTc]Tc-HFaPSMA was prepared by 99mTc radiolabeling of a HYNIC-conjugated bispecific biomolecule HFaPSMA, which combines a PSMA-targeting motif (PhPSMA), a FAP-targeting ligand (GFAPI), a symmetric PEG4-N-bis(PEG4-acid) linker, and a chelator (HYNIC). Preclinical studies showed faster clearance and higher tumor uptake than that of its corresponding single-target radiotracers ([99mTc]Tc-HPSMA and [99mTc]Tc-HGFAPI). Clinical SPECT/CT matched the resolution of [18F]FDG and [18F]F-PSMA-1007 PET/CT for primary and metastatic lesions. [99mTc]Tc-HFaPSMA showed excellent targeting specificity for both PSMA and FAP. It has the potential to overcome diagnostic limitations due to PSMA heterogeneity and is expected to advance its application in radioligand therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsGlutamate Carboxypeptidase IIRadiopharmaceuticalsAntigens, SurfaceOrganotechnetium CompoundsMaleHumansAnimalsMiceCell Line, TumorTissue DistributionTechnetiumPositron Emission Tomography Computed Tomography

Substanzen

Glutamate Carboxypeptidase IIRadiopharmaceuticalsFOLH1 protein, humanAntigens, SurfaceOrganotechnetium CompoundsTechnetium

Autor:innen und Institutionen

  • Department of Radiation Medicine, School of Basic Medical Sciences, Peking University, Beijing 100191, China.
  • Department of Nuclear Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, 277W Yanta Road, Xi'an 710061, China.

ORCID-Profile: Bing Jia

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Wang, Y., Li, X., Li, C., Xing, H., Gao, R., & Jia, B. (2025). A Novel PSMA/FAP-Specific Radiotracer 99mTc-HFaPSMA for Diagnosis of PSMA-Negative Prostate Cancer: From Preclinical Validation to Clinical Translation. Journal of Medicinal Chemistry, 68(16), 17598-17610. https://doi.org/10.1021/acs.jmedchem.5c01294

Vancouver

Wang Y, Li X, Li C, Xing H, Gao R, Jia B. A Novel PSMA/FAP-Specific Radiotracer 99mTc-HFaPSMA for Diagnosis of PSMA-Negative Prostate Cancer: From Preclinical Validation to Clinical Translation. Journal of Medicinal Chemistry. 2025;68(16):17598-17610. doi:10.1021/acs.jmedchem.5c01294

BibTeX
@article{Wang2025,
  author = {Wang, Yuchen and Li, Xinru and Li, Chenzhen and Xing, Huiyuan and Gao, Rui and Jia, Bing},
  title = {A Novel PSMA/FAP-Specific Radiotracer 99mTc-HFaPSMA for Diagnosis of PSMA-Negative Prostate Cancer: From Preclinical Validation to Clinical Translation},
  journal = {Journal of Medicinal Chemistry},
  year = {2025},
  volume = {68},
  number = {16},
  pages = {17598--17610},
  doi = {10.1021/acs.jmedchem.5c01294}
}
Kostenlos starten →